| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1997;114:923-933
© 1997 Mosby, Inc.
CARDIAC AND PULMONARY REPLACEMENT |
Received for publication March 11, 1997 Revisions requested April 22, 1997 Revisions received May 7, 1997 Accepted for publication May 7, 1997 Address for reprints: Hillel Laks, MD, Division of Cardiothoracic Surgery, UCLA Medical Center, 62-182A Center for the Health Sciences, 10833 Le Conte Ave., Los Angeles, CA 90095.
Abstract
Background: Intracoronary transfer and expression of recombinant genes in the intact heart is now feasible. In the transplant setting, local modulation of host immune responses by a genetically modified allograft may offer an attractive alternative to systemic immunosuppression. Methods: We tested the efficacy and in vivo effect of intracoronary transfer of two immunosuppressive cytokine genes. First-generation E1-deleted adenoviral vectors expressing the Epstein-Barr virus interleukin-10 (AdSvIL10) or human transforming growth factor—ß1 (AdCMVTGF-ß) were used. Rabbit cardiac allografts were transduced during cold preservation by slow (1 ml/min) intracoronary infusion of 1010 pfu/gm diluted viral vectors and then implanted heterotopically. Controls included E1-deleted adenovirus (Ad5dl434) and AdCMVLacZ. Beating allografts were collected on day 4 for analysis of gene transfer efficacy and distribution. Additional grafts were used for evaluation of alloreactivity (n = 34). Results: Mean allograft viral uptake was 81% (up to 91%). Polymerase chain reactions and reverse transcription–polymerase chain reactions confirmed the presence and expression of both genes in the grafts. ß-Galactosidase staining in AdCMVLacZ-infected grafts demonstrated efficient gene expression, which was highest (100%) in subepicardial regions. More homogeneous transmyocardial distribution of the transgene (in 25% to 40% of cells) could be achieved by pulsatile slow delivery. Allograft survival was 6.9 ± 0.9 days in controls (n = 12), 11.1 ± 1.7 days in AdCMVTGF-ß–infected grafts (n = 11, p < 10), and 11.2 ± 3 days in AdSvIL10-infected grafts (n = 11, p < 10). Histologic scores (blinded) showed significantly (p < 0.005) higher regression coefficients for rejection in controls compared with both cytokine-transduced groups. Perioperative administration of cyclosporine A (INN: ciclosporin) to recipients had no effect on survival of AdCMVTGF-ß–infected grafts but reduced survival of AdSvIL10-infected grafts. Conclusions: Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts is efficient and effectively prolongs graft survival. Vectors that would induce long-term expression of such genes may make this approach clinically applicable.
With the recently developed science of gene therapy, a new era in cardiovascular therapeutics has been opened. Localized expression of recombinant genes in the transplanted heart may contribute to the prevention and treatment of major problems in transplantation, such as allograft accelerated coronary atherosclerosis and acute rejection. An immediate application of allograft-targeted gene therapy is local modulation of the host immune response by a genetically altered allograft. Soluble proteins secreted within the transplanted organ may act locally and specifically while avoiding systemic side effects and the need for conventional systemic immunosuppression.
Gene transfer into the adult heart has been achieved in vivo by direct myocardial injection
1-5 and more recently by intracoronary infusion. 6-10 The latter method is preferable when considering clinical application, because direct injection results in uneven distribution of transgene expression and local inflammation. 4,5 By way of increasing the efficacy of gene transfer and facilitating recombinant DNA uptake by target cells, vehicles for gene transfer such as cationic liposomes, viral vectors, or a combination of both 10 have been successfully used. Given the specific attributes of nondividing cardiac cells, recombinant adenoviral vectors emerged as the most effective vehicle for transport of genes into the heart under both normothermic 7,9 and hypothermic 6 conditions. To date, studies of gene transfer in the heart have been largely limited to the use of reporter genes to demonstrate transgene expression and the efficacy of various transfer strategies.
To evaluate the applicability of intracoronary gene therapy for cardiac transplantation in vivo, we constructed first-generation recombinant adenoviral vectors encoding two immunosuppressive cytokines, viral interleukin-10 (vIL-10) and human transforming growth factor–ß1 (TGF-ß1). In addition to well-documented immunosuppressive properties in vitro, both have recently been shown to inhibit host responses in models of alloreactivity in vivo. IL-10, an 18 kd polypeptide initially described as cytokine synthesis inhibitory factor, is best known for its down-regulating action on the effector functions of Th1 helper clones, potently inhibiting production of IL-2, TNF-
, TNF-ß, and interferon-
. The activation of monocyte-macrophages is thus effectively suppressed, as is the release of monokines and their ability to serve as accessory cells for antigen presentation and stimulation of Th and natural killer cells. 11-13 The viral homologue (IL-10 homologue) used in this study is encoded by an open-reading frame (BCRF1) in the Epstein-Barr virus genome. 14 This protein shares most of the biologic activities of the cellular cytokine. Although it has lower in vitro potency, 11 it seems more suitable for targeted immunosuppression in alloreactivity models, because of lower mast cell and thymocyte co-stimulatory action. TGF-ß1 is an omnipresent cytokine, with potent down-regulating functions in both cellular and humoral alloreactive pathways. It suppresses clonal generation and production of IL-2, IL-6, and TNF by alloantigen-specific T lymphocytes at femtomolar levels 15,16 and effectively reduces killer activity and pore-forming protein gene expression in CD8+ lymphokine-activated killer cells. 17 In addition, B-cell proliferation and immunoglobulin production are greatly reduced.
We have previously tested the ability of the new E1-deleted adenoviral vectors to express the encoded cytokine genes in cardiac allografts, and have developed a model for efficient ex vivo intracoronary transfer of the cytokine genes during cold preservation. 18 The efficacy of various methods of vector delivery, as well as the dose-dependence of transgene expression, were evaluated. Continuous slow intracoronary infusion of diluted vectors was found superior to bolus high-pressure injection, resulting in absorption of up to 91% of infused vectors (mean 80%). This uptake rate was sustained with administered vector doses as high as 6 x 1010 pfu/gm of donor heart. An exposure time of at least 20 minutes was required to obtain detectable transgene expression in the allografts and recipient serum on postoperative day 4. This method of delivery resulted in measured tissue protein levels, as shown in Table I.
|
Methods
Viral vectors
A recombinant adenovirus expressing vIL-10 (AdSvIL10) was constructed as follows: A 520 bp EcoRI fragment containing the Epstein-Barr virus BCRF1 open reading frame (vIL-10) derived from pcDSR-BCRF1 14 (kindly provided by Dr. Kevin Moore, DNAX, Palo Alto, Calif.) was first cloned into a modified pBS SK+ (Stratagene Inc., La Jolla, Calif.), with its KpnI site changed to a BglII site, resulting in pBS-BCRFl. Then the BglII to BamHI BCRFl containing fragment from pBS-BCRFl was inserted between the SV40 early promoter and the SV40 polyA site of pAdDB. pAdDB is derived from a pUC-based plasmid pAd2.17 19 containing Ad2 left end sequences from nucleotide 1 to 6228 (HindIII site) with its E1 region from nucleotide 341 to 3321 replaced by an expression cassette containing an SV40 early promoter, splice site, and polyA site from pXPRS+ (Clontech Inc., Palo Alto, Calif.). In the resultant plasmid pAdSvIL10, the direction of vIL-10 gene transcription is leftward relative to the standard Ad2 map. AdSvIL10 recombinant virus was constructed by co-transfection of 293 cells (that constitutively express E1 proteins) with pAdSVvIL10 and dl309 viral DNA 20 cut with XbaI and ClaI. Clones of recombinant virus were identified by restriction digestion and Southern blot analysis of Hirt DNA from infected 293 cells.
The AdCMVTGF-ß1 was constructed as follows: the 1.3 kb hTGF-ß1 complementary DNA (cDNA) fragment, flanked by EcoRI sites, was cloned into the EcoRI site of pHCMVsp1lacZ, 21 replacing the LacZ gene. The resultant plasmid pHCMVhTGF-ß has the human TGF-ß gene downstream from the CMV IE promoter and contains the SV40 splice signal and polyA site. Co-transfection into 293 cells with pHCMVhTGF-ß and truncated dl309 viral DNA resulted in generation of AdCMVTGF-ß1.
The control "empty" virus Ad5dl434 has deletions of the entire E1A and most of the E1B region. 22 The AdCMVLacZ virus, which encodes the E. coli LacZ gene with an N-terminal nuclear localization signal, was constructed by co-transfection of pACCMVßgal (kindly provided by Robert D. Gerard) and pJMl7. 23
All recombinant viruses were plaque purified on 293 cells three successive times and grown into a high titer stock of greater than 1010 pfu/ml as assayed by plaque formation on 293 cells. The ability of cytokine-encoding vectors to express the transgenes was confirmed by enzyme-linked immunosorbent assay detection of both vIL-10 and TGF-ß1 24 hours after infection in 293 cell culture supernatant.
Experimental procedures
The rabbit heterotopic model of cardiac transplantation was previously described. 18 In brief, New Zealand White donors (1.7 to 2 kg, Charles River Laboratories, St. Constant, Quebec, Canada) and recipients (5 to 5.5 kg, Irish Farms, Norco, Calif.) were purchased from genetically and geographically unrelated vendors. All animals received humane care in compliance with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical Research and the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 86-23; revised 1985). General anesthesia was induced intravenously with ketamine (10 mg/kg) and acepromazine (1 mg/kg) and maintained with inhaled 1.5% isoflurane in oxygen by means of mechanical ventilation. Heparin (200 mg/kg) was given intravenously to both donors and recipients. Recipients received cefazolin (40 mg/kg) before incision. After sternotomy, the donor heart was arrested with University of Wisconsin solution (15 ml), then excised and preserved in University of Wisconsin solution at 4° C. After intracoronary gene transfer (see below), donor hearts were transplanted in recipients in the heterotopic cervical position, by anastomosing the donor aorta and pulmonary artery to the recipient right carotid artery and jugular vein, respectively. Topical cooling of donor hearts was maintained throughout the procedure. Ischemic time was 50 to 60 minutes. All allografts resumed spontaneous vigorous contraction within minutes of reperfusion. Cessation of mechanical activity before day 4 occurred in 10% and was considered to be due to technical failure.
Intracoronary gene transfer
During preservation at 4° C, the donor aorta was cannulated. Viral vectors were resuspended in 20 ml cold University of Wisconsin cardioplegic solution and administered by slow intracoronary infusion at 1 ml/min. The total vector dose of 1010 pfu/gm of donor heart (mean weight 5 to 5.5 gm) was infused over 20 minutes. This constitutes an estimated multiplicity of infection of 20 viral particles per cell. After administration of at least 10 ml, coronary sinus effluent was collected for determination of viral titers.
Specimen processing
Allografts were inspected twice daily by direct palpation and given a score for mechanical activity, size, and consistency. For evaluation of cytokine transcripts and reporter gene expression, specimens were collected on postoperative day 4. For evaluation of allogenicity, other grafts were collected when mechanical activity became imperceptible. Transmural specimens from the left and right ventricular free walls and intraventricular septum were collected for each allograft.
PCR
Flanking primers were designed for internal regions of both transgenes: for vIL-10—a 461 bp region (sense: 5`-ATGGAGCGAAGGTTAGTGGTC A-3`, antisense: 5`-CCTGGCTTTAATTGTCATGTATGCT-3`); for TGF-ß1—a 243 bp region (sense: 5`-GCCCTGGACACCAACTATTGC-3`, antisense: 5`-TTGCGGCCCACGTAGTACA-3`). DNA was extracted from specimens snap-frozen after cessation of mechanical activity, by the proteinase K incubation method: samples were crushed to fine powder and suspended in digestion buffer (100 mmol/L NaCl, 10 mmol/L tromethamine-Cl, 25 mmol/L ethylenediaminetetraacetic acid, 0.5% sodium dodecylsulfate, pH 8.0, 0.l mg/ml proteinase K) at 80 mg/ml for 1 hour. Phenol/chloroform/isoamyl alcohol (25:24:1) was added in equal volume, and then the upper aqueous phase was separated by centrifugation. This step was repeated with and without chloroform; then two volumes of 100% ethanol and 10% sodium acetate (pH 5.2) were added at –20° C for 1 hour. DNA precipitate was dried and resuspended in water at room temperature. PCR was performed in a DNA thermal cycler (Perkin-Elmer, Norwalk, Conn.) and consisted of 30 cycles (denaturing: 94° C-1`; annealing of primers: 55° C-1`; and extension: 72° C-1`). PCR products were separated by electrophoresis in 1.2% agarose gel and then stained with ethidium bromide. Expression plasmids used for vector construction served as positive controls.
RT-PCR
Total RNA was isolated from frozen specimens collected 4 days after the operation, by means of the lithium chloride/urea method. 24 cDNA was obtained by random primer reverse transcription of RNA using 200 units of SuperScript II Reverse Transcriptase (Gibco-BRL RT-PCR kit, Gaithersburg, Md.). The RNA/primer mixture was incubated at 42° C for 60 minutes, then 70° C for 15 minutes. cDNA was amplified with 1 unit of Taq DNA polymerase (Gibco-BRL) and 0.2 µM of each primer to a final volume of 100 µl, using the two specific primers described above for vIL-10 and human TGF-ß1. Thirty-five cycles of amplification were carried out in a thermocycler (GeneAmp PCR System 9600, Perkin-Elmer) and consisted of denaturing at 94° C for 30 minutes, primer annealing at 55° C for 45 minutes, and primer extension at 72° C for 30 minutes. Before cycling, the reaction mixtures were preheated at 94° C for 2 minutes and after amplification an extra 10 minutes were added for extension at 72° C. RT-PCR products were run on 1.2% agarose gel, transferred to nylon membranes, and probed for the presence of vIL-10 and TGF-ß1 using a random primer (32P) dATP-labeled probe.
ß-Galactosidase expression
Normally contracting grafts were collected on postoperative day 4, and specimens were embedded in ornithine carbamoyltransferase (O.C.T.), then rapidly frozen in liquid nitrogen. Sections 10 µm thick were fixed in 0.2% glutaraldehyde and 2% formaldehyde in phosphate-buffered saline (PBS) solution for 5 minutes at 4° C. After being washed three times with phosphate-buffered saline solution at room temperature, the sections were stained for ß-galactosidase by overnight incubation with X-gal (5-bromo-4-chloro-indolyl ß-D-galactopyranoside) at 37° C. Cells expressing ß-galactosidase showed intense blue staining. To quantify expression, positive as well as total cells were counted per high-power field (x400). At least 10 fields per specimen from different subepicardial and subendocardial areas were examined.
Histologic examination
After graft failure, transmural specimens from the left and right ventricular free walls and intraventricular septum were fixed in 10% formalin. Slices 10 µm thick were stained with hematoxylin and eosin. Rejection scores were assigned by a pathologist unaware of study design, based on the standard grading nomenclature established by the International Society for Heart Transplantation. 25
Data analysis
Data are expressed as mean ± standard deviation. Allograft survival curves produced with the Kaplan-Meier product limit method were compared with the Mantel-Cox log rank test. Rejection slope coefficients were compared with the use of one-way analysis of variance and significant differences were further tested by means of the Bonferroni t test for multiple comparisons. Significance level was set at p < 0.05.
Results
Vector absorption, detection, and expression
Using intracoronary delivery at a rate of 1 ml/min and vector quantity of 1010 pfu/gm of donor heart, average uptake of vectors by the grafts (defined as coronary sinus output titer x 100/delivered titer) was 81% ± 5.6%. All four vectors were absorbed equally. Inserted cytokine DNA sequences were detected by amplification (PCR) in all grafts infected with the AdSvIL10 and AdCMVTGF-ß (Fig. 1, a), but not in controls. This finding is consistent with the presence of both transferred genes in graft tissue after cessation of mechanical activity. RT-PCR (Fig. 1, b) demonstrated the presence of both cytokine transcripts in the grafts, confirming successful gene transfer and expression in myocardial cells on postoperative day 4.
|
|
Mean survival for AdCMVTGF-ß–infected grafts (n = 11) was 11.1 ± 1.7 days (range 9 to 15.5 days, p < 10-4 compared with controls). All but one graft in this group survived 10 days or longer, with clinical rejection starting at 8 to 13 days.
AdSvIL10-infected allografts (n = 11) survived for an average of 11.2 ± 3 days (p < 10 compared with controls). Although graft survival was distinctly prolonged by vIL-10 gene transfer, allografts in this group seemed to fall in two separate categories, surviving either 8 to 9.5 days (n = 7) or 14 to 16.5 days (n = 4). This finding could not be attributed to any specific divergence in treatment, including vector delivery, ischemic time, or other surgical or experimental factors. Clinical allograft deterioration started, correspondingly, either on day 7 or after day 13 postoperatively. Kaplan-Meier cumulative survival curves were derived for the three groups (Fig. 3).
|
|
26 As shown in Fig. 5, survival of AdCMVTGF-ß–infected grafts (n = 4) was not affected by perioperative administration of cyclosporine A. However, an unexpected reduction in survival of AdSvIL10-infected allografts (n = 4, p = 0.003) was observed, to the level of control Ad5dl434-infected grafts.
|
The present study constitutes a first report of a working allograft-targeted gene therapy strategy in the heart transplant setting. It demonstrates the ability of exogenous immunosuppressive cytokine genes delivered by ex vivo intracoronary gene transfer to effect a significant inhibitory action on acute allograft rejection. Adenovirus-mediated delivery of both the vIL-10 and human TGF-ß1 genes during allograft cold preservation resulted in efficient vector uptake, internalization, transcription, and intragraft expression of both cytokines. Prolongation of allograft survival, although temporary, was evident and highly significant, suggesting that this approach may be used to facilitate transplantation.
Recent studies from this and other laboratories have qualitatively demonstrated the feasibility of intracoronary myocardial gene transfer, using cationic liposomes and adenoviral vectors. 6,8-10,27 Replication-defective adenoviral vectors are currently the most efficient vehicle for in vivo gene transfer into nondividing cells such as myocytes, being at least 20 times more potent than the newest liposomal compounds. 28 Exogenous DNA up to 8.3 kb can be used to replace the viral early expression regions E1 and E3 or partly E4. 29 Although the use of viral vectors in vivo raises safety concerns, the widespread type 5 adenovirus has not been associated with any known malignancies and has been used for routine vaccination in human beings with no apparent side-effects. 30 The viral particle enters the cell by way of a two-stage process: high-affinity membrane binding occurs by way of the fiber protein, a step that is unaffected by hypothermic conditions. Internalization is then mediated by interaction of the penton base with cellular alpha v beta 3 and 5 integrins (the vibronectin-binding proteins). 31 This process is energy-dependent and occurs under normothermic conditions after graft reperfusion. After endocytosis and cytoplasmic release of the fiber, penton base, and capsid-stabilizing proteins, up to 80% of internalized viral particles reach the nucleus, where the viral genome remains episomal, thus resulting in transient expression. 32 This short-lived duration of transgene expression currently limits the potential usefulness of first-generation adenoviral vectors for in vivo gene therapy.
The current study first evaluated the magnitude and transmural distribution of gene expression in allografts infected during cold preservation with adenoviral vectors encoding a reporter gene (ß-galactosidase). The use of reporter genes allows direct visualization of the transduced cells by enzymatic staining, thus having the advantage of easy localization of gene expression. The efficacy of gene transfer obtained in the present study by slow low-pressure intracoronary infusion of vectors under hypothermic conditions is comparable with that previously reported with normothermic transcatheter intracoronary infusion in vivo 7 and represents the highest myocardial transduction ratios to date. However, transmural expression of vectors administered in this fashion was not homogeneous: whereas subepicardial perivascular regions were transduced with very high efficacy, ß-galactosidase expression in subendocardial areas was considerably lower. This finding may be due to high-affinity adherence of the vectors to proximal first-encountered cells, made possible by the slow delivery rate. When soluble cytokine genes are being transferred, this may not necessarily lessen an in vivo effect, because secreted proteins may act within the graft without requiring uniform myocardial expression. Nevertheless, some gene transfer applications (e.g., neoangiogenesis or enhancement of contractile function) may require homogeneous transgene distribution. We demonstrated that a more uniform distribution of transgene expression throughout the myocardium can be achieved by pulsatile administration of the vectors at higher perfusion pressure without reducing the duration of inflow, a method easily applicable clinically.
In the present study, an initial 60% prolongation of allograft survival was followed by graft rejection, suggesting that cytokine levels were temporarily sufficient to achieve an in vivo effect. The time course of graft failure corresponds to the time frame of adenoviral vector transgene expression as documented by reports of in vivo gene transfer. 6,7,33 It is therefore plausible that the decline in cytokine expression be a reason for graft failure. The mechanism causing the transience of expression of genes transferred by adenoviral vectors is not fully understood. Cellular and humoral host immune responses have been shown to be activated against both the adenovirus group antigen and the encoded transgene within 2 weeks of intramuscular vector administration in mice, and systemic immunosuppression has significantly prolonged gene expression. 34 However, liposomal gene delivery results in only marginal prolongation of expression. More recently, it has been suggested that humoral immune response to non-self transgene-encoded proteins, rather than viral proteins, is responsible for this observed instability of transgene expression, as well as the relative inefficacy of repeated vector administration. 35 Whereas TGF-ß1 has down-regulating effects on B-cell proliferation and antibody production, vIL-10 actually promotes differentiation and proliferation of B cells along their maturation stages. 12 This opposed action on humoral responses might explain the more consistent prolongation of allograft survival observed with TGF-ß1. The finding that transfer of a self-protein gene results in stable long-term expression under identical conditions in immunocompetent animals 35 is encouraging, because most candidates for clinical gene therapy applications are ubiquitous proteins such as cytokines, enzymes, receptors, and growth factors. 36 Future research should evaluate the usefulness of gene therapy strategies inducing overexpression of such self-proteins.
A vector absorption ratio above 80% was maintained in the present study with all four vectors. We previously found the absorbed fraction of adenoviral vectors administered by ex vivo slow intracoronary infusion to be remarkably constant over a wide range of doses, despite hypothermic (4° C) conditions. Moreover, expression of TGF-ß1 correlated with the infused (and absorbed) quantity of AdCMVTGF-ß in a dose-dependent manner. 18 These results are encouraging, because high doses of vectors may be administered without saturating allograft receptors and may increase the initial amount of expressed protein. The detection of both expressed cytokines in corresponding recipient serum (see 
Table I) suggests that a significant amount of protein is secreted by the allografts. Although it cannot be ruled out that part of this protein is secreted by remote recipient cells infected with virus shed from the coronary bed during graft reperfusion, we believe this amount to be small, based on the small volume of the rabbit coronary tree and the high dilution of administered virus. However, we cannot rule out the possibility of a systemic immunosuppressive effect mediated by the secreted cytokine fraction. In a recent report, prolongation of the survival of nonperfused neonatal mouse donor hearts transduced by retrovirus-mediated transfer of the vIL-10 gene was found to be due to local rather than systemic immunosuppression. 37 However, vIL-10 was not detectable in the serum of recipient mice in that report.
Perioperative administration of high-dose cyclosporine A failed to further prolong allograft survival. The rationale for cyclosporine A administration at this time was to provide transient inhibition of cellular immune activation and antigen-presenting cell function for the duration of initial transcription and translation of the inserted genes. These processes occur immediately after graft reperfusion and, therefore, are not within the time frame of transgene expression. Although cyclosporine A had no effect on survival of AdCMVTGF-ß–infected grafts, the survival of AdSvIL10-infected grafts was significantly shortened by perioperative administration of cyclosporine A. Inadequate time frame or magnitude of cyclosporine A–induced immunosuppression may partly explain these results; however, an important difference between the two cytokines lies in their different interspecies homology. Whereas TGF-ß1 is highly similar between species, IL-10 varies structurally and functionally. 13 In our rabbit model, vIL-10 allogenicity may have precipitated an accelerated immune response to this non-self encoded protein in the setting of delayed antigen presentation effected by cyclosporine A. A recent finding by van Bergen and associates 38 may provide a clue to the mechanism of IL-10-mediated acceleration of graft rejection in the presence of antigen-presenting cell suppression. Although IL-10 is known to inhibit antigen-induced T-cell proliferation in the presence of antigen-presenting cells, the authors found that in the absence of antigen-presenting cells, this cytokine strongly stimulated proliferation of CD8+ cytotoxic T-lymphocyte clones. These in vitro results suggest a dichotomy of IL-10 immunomodulatory function early and late in the allogeneic immune response. To determine the mechanisms by which the two cytokines exert their immunosuppressive effect in vivo, further research will include an analysis of the graft cellular infiltrate and quantitation of alloantigen-specific cytotoxic and helper T-cell precursors, in addition to cytokine expression profiles within the grafts.
The ability to transfer working recombinant genes to cardiac allografts at the time of preservation, as demonstrated in the present study, has potentially far-reaching clinical and research applications. In the long term, this approach may be part of a strategy to provide a milieu in which organ-specific tolerance may be achieved by the use of adjuvant time-limited measures. In addition, therapies involving gene transfer can be envisioned that would improve early posttransplantation myocardial contractility and endothelial function or prevent late allograft vasculopathy. However, the limitations of currently available vectors must first be overcome to improve the stability of transgene expression. Promising strategies aimed at extending the expression of transferred genes include further deletions in second- and third-generation adenoviruses, 39,40 systemic immunosuppression, 34 use of self-protein encoding genes, 35 use of genome-integrating vectors, 37,41 and construction of new recombinant vectors. Especially promising is the recent demonstration of long-term myocardial transgene expression induced by transcatheter intracoronary delivery of adeno-associated viral vectors. 42 The use of this genome-integrating vector has been impeded until recently by the difficulty of obtaining high viral titers free of helper adenovirus contamination, but this may no longer be an obstacle. 43 If successful, allograft-targeted gene therapy alone or a combination of gene transfer with time-limited pharmacologic interventions may prove to be an important alternative to conventional systemic immunosuppression.
References
This article has been cited by other articles:
|
|
 |
|
  G. Vassalli, M.-E. Roehrich, P. Vogt, G. B. Pedrazzini, F. Siclari, T. Moccetti, and L. K. von Segesser Modalities and future prospects of gene therapy in heart transplantation Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 1036 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Gallaher, J. S. Gil, O. Dorigo, and A. J. Berk Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector J. Virol., April 1, 2009; 83(7): 3249 - 3257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Abunasra, R. T. Smolenski, J. Yap, J. Jayakumar, M. Sheppard, and M. H. Yacoub Comparison of two gene transfer models for the attenuation of myocardial ischemia-reperfusion injury following preservation for cardiac transplantation. Eur. J. Cardiothorac. Surg., May 1, 2006; 29(5): 772 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miyamoto, T. Kaneko, M. Yamashita, Y. Tenda, M. Inami, A. Suzuki, S. Ishii, M. Kimura, K. Hashimoto, H. Shimada, et al. Prolonged skin allograft survival by IL-10 gene-introduced CD4 T cell administration Int. Immunol., June 1, 2005; 17(6): 759 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Furukawa, K. Oshima, T. Tung, G. Cui, H. Laks, and L. Sen Liposome-Mediated Combinatorial Cytokine Gene Therapy Induces Localized Synergistic Immunosuppression and Promotes Long-Term Survival of Cardiac Allografts J. Immunol., June 1, 2005; 174(11): 6983 - 6992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau Gene- and cell-based therapies for cardiovascular diseases: current status and future directions Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. G. MELO, A. S. PACHORI, D. KONG, M. GNECCHI, K. WANG, R. E. PRATT, and V. J. DZAU Gene and cell-based therapies for heart disease FASEB J, April 1, 2004; 18(6): 648 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vassalli, S. Fleury, J. Li, J.-J. Goy, L. Kappenberger, and L. K. von Segesser Gene transfer of cytoprotective and immunomodulatory molecules for prevention of cardiac allograft rejection Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 794 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Tung, K. Oshima, G. Cui, H. Laks, and L. Sen Dual upregulation of Fas and Bax promotes alloreactive T cell apoptosis in IL-10 gene targeting of cardiac allografts Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H964 - H973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Abunasra, R. T. Smolenski, J. Yap, M. Sheppard, T. O'Brien, and M. H. Yacoub Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 998 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sen, Y.-S. Hong, H. Luo, G. Cui, and H. Laks Efficiency, efficacy, and adverse effects of adenovirus- vs. liposome-mediated gene therapy in cardiac allografts Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1433 - H1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Avery Viral Triggers of Cardiac-Allograft Dysfunction N. Engl. J. Med., May 17, 2001; 344(20): 1545 - 1547. [Full Text] [PDF]
|
|
|
|
|
|
B. N. Mora, C. H. R. Boasquevisque, M. Boglione, J. M. Ritter, R. K. Scheule, N. S. Yew, L. Debruyne, L. Qin, J. S. Bromberg, and G. A. Patterson Transforming growth factor-{beta}1 gene transfer ameliorates acute lung allograft rejection J. Thorac. Cardiovasc. Surg., May 1, 2000; 119(5): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pellegrini, A. Jeppsson, C. B. Taner, T. O’Brien, V. M. Miller, H. D. Tazelaar, and C. G. A. McGregor HIGHLY EFFICIENT EX VIVO GENE TRANSFER TO THE TRANSPLANTED HEART BY MEANS OF HYPOTHERMIC PERFUSION WITH A LOW DOSE OF ADENOVIRAL VECTOR J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Mora, C. H.R. Boasquevisque, G. Uy, T. J. McCarthy, M. J. Welch, M. Boglione, and G. A. Patterson Exhaled nitric oxide correlates with experimental lung transplant rejection Ann. Thorac. Surg., January 1, 2000; 69(1): 210 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, Y.-y. Zhang, M. Ogata, P. Chen, A. Harada, S.-i. Hashimoto, and K. Matsushima Transforming Growth Factor-beta 1 Polarizes Murine Hematopoietic Progenitor Cells to Generate Langerhans Cell-Like Dendritic Cells Through a Monocyte/Macrophage Differentiation Pathway Blood, February 15, 1999; 93(4): 1208 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
